English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

www.jogh.org • doi: 10.7189/jogh.09.010305 1 June 2019 • Vol. 9 No. 1 • 010305 The recent Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) cluster-randomised trial of mass azithromycin administration in Malawi, Niger and Tanzania demonstrated a 13.5% overall reduction in under-5 childhood mortality among communities receiving twice-yearly azithromycin [1]. Subgroup analyses suggested that these mortality reductions were consistent only in children <6 months, and that overall results were mainly driven by mortality reductions in Niger, where both mortality and mortality reductions were considerably greater than in the other two countries. Uncertainty in effect estimates from Malawi and Tanzania was high, because baseline mortality in these two countries was much lower than assumed in the trial design.

One drug to treat them all: ethical implications of the MORDOR trial of mass antibiotic administration to reduce child mortality